drugset
drugset / Trial / NCT01474434

Efficacy of LCQ908 on Cardiovascular Risk

NCT01474434 ↗

Phase 2 Terminated 41 enrolled Novartis Pharmaceuticals
RandomizedCrossoverTriple-blindTreatment

Summary

This is a study designed to evaluate the potential for the pradigastat (LCQ908) to impact cardiovascular risk.

Timeline

Start
2011-12
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Pradigastat Small molecule 20 mg —

Indications

coronary artery disorder hypertriglyceridemia